Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study

[1]  E. Lewiecki,et al.  HIP FRACTURES AND DECLINING DXA TESTING: AT A BREAKING POINT? , 2017 .

[2]  M. Etminan,et al.  Oral Bisphosphonates and Risk of Wet Age-Related Macular Degeneration. , 2016, American journal of ophthalmology.

[3]  S. Khosla,et al.  A Crisis in the Treatment of Osteoporosis , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  K. Saag,et al.  A pragmatic randomized trial comparing tablet computer informed consent to traditional paper-based methods for an osteoporosis study , 2016, Contemporary clinical trials communications.

[5]  Smita Jha,et al.  Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996–2012: An Ecological Analysis , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  Jingwei Wu,et al.  Operating characteristics of PROMIS four-item depression and anxiety scales in primary care patients with chronic pain. , 2014, Pain medicine.

[7]  R. Francis,et al.  Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. , 2014, Health technology assessment.

[8]  D. Wysowski,et al.  Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. , 2013, Bone.

[9]  P. Muntner,et al.  Generic alendronate use among medicare beneficiaries: are part d data complete? , 2013, Pharmacoepidemiology and drug safety.

[10]  S. Boonen,et al.  Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long‐term continuation on bone turnover and fracture risk—a perspective , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  J. Bilezikian,et al.  Bisphosphonate therapy for osteoporosis: The long and short of it , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  Thomas D Brown,et al.  Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  S. Reise,et al.  Item Banks for Measuring Emotional Distress From the Patient-Reported Outcomes Measurement Information System (PROMIS®): Depression, Anxiety, and Anger , 2011, Assessment.

[14]  C. Cooper,et al.  Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards , 2011, Osteoporosis International.

[15]  Klaus Klaushofer,et al.  Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  Gabriela Czanner,et al.  Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort , 2010, BMJ : British Medical Journal.

[17]  M. Seibel,et al.  Atypical femoral fractures and bisphosphonate use. , 2010, The New England journal of medicine.

[18]  Jacques P. Brown,et al.  Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  D. Wysowski.  Reports of esophageal cancer with oral bisphosphonate use. , 2009, The New England journal of medicine.

[20]  B. Steele,et al.  Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study , 2009, Osteoporosis International.

[21]  R. Eastell,et al.  Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register‐Based National Cohort Study , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  J. Reginster,et al.  Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial , 2009, The Lancet.

[23]  Jacques P. Brown,et al.  Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  J. S. San Martin,et al.  Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. , 2008, Bone.

[25]  J. Reginster,et al.  Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. , 2008, Bone.

[26]  D. Lorich,et al.  Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. , 2008, The New England journal of medicine.

[27]  S. Boonen,et al.  Teriparatide or alendronate in glucocorticoid-induced osteoporosis. , 2007, The New England journal of medicine.

[28]  S. Silverman,et al.  Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  J. Cauley,et al.  Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures. , 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.

[30]  A. Goss,et al.  Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. , 2007, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[31]  S. Cummings,et al.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. , 2006, JAMA.

[32]  L. Rubenstein.  Falls in older people: epidemiology, risk factors and strategies for prevention. , 2006, Age and ageing.

[33]  J. Zerwekh,et al.  Severely suppressed bone turnover: a potential complication of alendronate therapy. , 2005, The Journal of clinical endocrinology and metabolism.

[34]  M. Hochberg,et al.  Treatment With Once‐Weekly Alendronate 70 mg Compared With Once‐Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double‐Blind Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  Richard Birtwhistle,et al.  Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. , 2003, BMC medical research methodology.

[36]  T. J. Rosenberg,et al.  Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. , 2004, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[37]  S. Ott.  Fractures after long-term alendronate therapy. , 2001, The Journal of clinical endocrinology and metabolism.

[38]  B. DíazLópez,et al.  Bisphosphonates in the treatment of osteoporosis , 2000 .

[39]  Z. Fojtík,et al.  [Bisphosphonates in the treatment of osteoporosis]. , 1997, Vnitrni lekarstvi.

[40]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[41]  D. Bauer,et al.  Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. , 2013, The American journal of medicine.

[42]  J. S. San Martin,et al.  Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial , 2009 .

[43]  Donald A. Berry,et al.  Statistical Innovations in Cancer Research , 2003 .